Latest Developments in Rare Disease Policy Rare diseases collectively affect millions of patients worldwide, yet each individual condition impacts a relatively small population. Historically, li...
Latest Developments in the Biosimilar Market The global pharmaceutical industry is witnessing rapid growth in the biosimilars market as patents for several blockbuster biologic drugs begin to ex...
Key Highlights: Implications: Oncology ace Vanneste turbocharges MSD’s immuno-oncology push against Roche/Pfizer, targeting India’s exploding cancer caseload with ke...
Key Highlights: Implications: Zydus’ smart-pen assault smashes generic pricing barriers, handing endocrinologists flexible dosing that trumps competitor pens while exploding Tier-2 a...
Key Highlights: Implications: Semaglutide generics could slash Novo Nordisk pricing by 70-80% in India’s $2.5B diabetes market (12% CAGR), capturing 25%+ share and pressuring chronic...
Emerging Technology Trends in Biopharma The intersection of technology and biopharma isn’t a futuristic idea anymore it’s happening right now. Artificial intelligence (...
Key Highlights: Implications: Lilly’s India manufacturing bet locks in low-cost production muscle, outflanking China-dependent rivals as Mounjaro mania drives capacit...
Key Highlights: Implications: PEPAIR smashes cost barriers to OPEP therapy, handing pulmonologists a game-changing tool that slots perfectly alongside Zydus inhalers and Deriphyllin....
Key Highlights: Implications: Sanofi’s Hyderabad bet signals all-in pharma offshoring, vacuuming up AI/data talent that smaller players can’t touch while crushi...
Key Highlights: Implications: India’s GATINN catapults Servier into SPC dominance, crushing fragmented chronic therapy rivals while exploding patient compliance across emerging marke...
